HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Alberto-Culver Considering Sale Of Indola Hair Care

This article was originally published in The Rose Sheet

  • News
  • The Rose Sheet

Executive Summary

Alberto-Culver CEO Howard Bernick confirmed reports the company is considering the sale of a small European hair care line called Indola to Henkel during a fiscal second quarter (ended March 31) sales and earnings call with analysts April 22

You may also be interested in...



Dial To Bring Henkel Technology To U.S. Personal Care Brands

Dial plans to enhance its personal care portfolio in North America by introducing Henkel formulas under the Dial brand name, Dial CEO Herb Baum said May 5 at a Henkel analyst meeting in New York City

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Table

View full table

Tags:
Latest Headlines

Probiotics And Cold Remedies Boost Recordati In 2023

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

P&G Restores Volume Growth In Beauty, Grooming After Pricing Run

Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches

See All
UsernamePublicRestriction

Register

RS012064

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By